- Home
- ELVN vs ROOT Comparison
ELVN vs ROOT Comparison
Compare ELVN & ROOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- ROOT
- Stock Information
- Founded
- ELVN 2016
- ROOT 2015
- Country
- ELVN United States
- ROOT United States
- Employees
- ELVN N/A
- ROOT N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- ROOT Property-Casualty Insurers
- Sector
- ELVN Health Care
- ROOT Finance
- Exchange
- ELVN Nasdaq
- ROOT Nasdaq
- Market Cap
- ELVN 1.2B
- ROOT 2.3B
- IPO Year
- ELVN 2020
- ROOT 2020
- Fundamental
- Price
- ELVN $21.35
- ROOT $75.65
- Analyst Decision
- ELVN Strong Buy
- ROOT Buy
- Analyst Count
- ELVN 5
- ROOT 6
- Target Price
- ELVN $41.20
- ROOT $124.40
- AVG Volume (30 Days)
- ELVN 421.5K
- ROOT 517.6K
- Earning Date
- ELVN 11-12-2025
- ROOT 11-05-2025
- Dividend Yield
- ELVN N/A
- ROOT N/A
- EPS Growth
- ELVN N/A
- ROOT N/A
- EPS
- ELVN N/A
- ROOT 4.73
- Revenue
- ELVN N/A
- ROOT $1,364,700,000.00
- Revenue This Year
- ELVN N/A
- ROOT $27.41
- Revenue Next Year
- ELVN $20.05
- ROOT $9.74
- P/E Ratio
- ELVN N/A
- ROOT $15.98
- Revenue Growth
- ELVN N/A
- ROOT 59.76
- 52 Week Low
- ELVN $13.30
- ROOT $36.87
- 52 Week High
- ELVN $30.03
- ROOT $181.14
- Technical
- Relative Strength Index (RSI)
- ELVN 57.25
- ROOT 32.76
- Support Level
- ELVN $19.98
- ROOT $79.25
- Resistance Level
- ELVN $22.42
- ROOT $87.50
- Average True Range (ATR)
- ELVN 0.95
- ROOT 4.80
- MACD
- ELVN 0.17
- ROOT -0.87
- Stochastic Oscillator
- ELVN 71.20
- ROOT 4.65
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.